{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Kiniksa Pharmaceuticals International Plc
Kiniksa Pharmaceuticals: A Multibagger with 140.68% Return and Strong Financial Metrics
Kiniksa Pharmaceuticals International Plc has recently undergone a revision in its score, reflecting its strong operational performance and market position. The company reported significant growth in operating profit and net sales, alongside a solid financial foundation, making it an attractive option for investors in the pharmaceuticals sector.
Kiniksa Pharmaceuticals Hits New 52-Week High of $39.60
Kiniksa Pharmaceuticals International Plc achieved a new 52-week high of USD 39.60 on October 24, 2025, highlighting its strong performance in the pharmaceuticals sector. The company reported a 44.61% return over the past year and impressive financial metrics, indicating solid operational health and growth potential.
Kiniksa Pharmaceuticals Hits New 52-Week High of USD 39.12
Kiniksa Pharmaceuticals International Plc achieved a new 52-week high of USD 39.12 on October 1, 2025, reflecting strong performance in the pharmaceuticals sector. The company reported a 54.56% return over the past year, significant net profit growth, and a solid balance sheet, showcasing its resilience in a competitive market.
Kiniksa Pharmaceuticals Hits New 52-Week High of $38.97
Kiniksa Pharmaceuticals International Plc achieved a new 52-week high of USD 38.97 on September 30, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company reported a 52.30% return over the past year and impressive net profit growth of 108.83%, highlighting its operational strength.
Is Kiniksa Pharmaceuticals International Plc technically bullish or bearish?
As of October 1, 2023, Kiniksa Pharmaceuticals is in a bullish technical position, with positive indicators across multiple time frames, and has significantly outperformed the S&P 500 year-to-date with an 81.60% return compared to 12.22%.
Is Kiniksa Pharmaceuticals International Plc overvalued or undervalued?
As of August 11, 2025, Kiniksa Pharmaceuticals International Plc's valuation has shifted from fair to attractive, indicating it may be undervalued despite a high P/E ratio of 565.79 and an EV to EBITDA ratio of 402.35, while outperforming the S&P 500 with an 81.60% year-to-date return.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
